Cardiomyopathy caused by antineoplastic therapies
- 74 Downloads
The goals of care for patients at risk for cardiomyopathy induced by cancer treatment should include prevention, early diagnosis, treatment of subclinical cardiac dysfunction, prevention of disease progression, and prolongation of patient survival. Any strategy aimed to minimize the cardiotoxic effects of cancer treatment should maintain the treatment’s antineoplastic efficacy. Successful therapy achieves the highest health-related quality of life that is defined by the balance between maximizing the efficacy of oncologic therapy and minimizing the toxicity of this therapy. Doxorubicin-induced cardiotoxicity can be reduced by limiting the overall cumulative dose.
There is no specific treatment for cancer therapy-related cardiomyopathy, and symptomatic patients should receive standard treatments for congestive heart failure such as afterload reduction, beta-blockers, diuresis, and digoxin. Afterload reduction with angiotensin-converting enzyme inhibitors such as enalapril and captopril may be indicated in patients with elevated afterload and asymptomatic left ventricular dysfunction diagnosed by echocardiography. Beta-blockers may improve myocardial systolic dysfunction and may be useful in the treatment of cancer treatment-induced cardiomyopathy.
Cardiac transplantation remains a viable option in patients with cancer treatment-induced end-stage heart disease.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Stone RM, Bridges KR, Libby P: Hematological-oncological disorders and cardiovascular disease. In Heart Disease, edn 6. Edited by Braunwald E, Zipes DP, Libby P, et al. Philadelphia: WB Saunders Co; 2001:2223–2243.Google Scholar
- 4.Von Hoff DD, Layard MW, Basa P, et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710–717.Google Scholar
- 18.Adams MJ, Constine LS, Lipshultz SE: Radiation. In Cardiology. Edited by Crawford MH, Dimarco JP. London: Mosby International Ltd; 2001:15.1–15.8. This chapter provides a comprehensive review of radiation associated heart disease, including pathology, clinical presentation, screening, and treatment.Google Scholar
- 25.Heart Failure Guideline Panel: Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. Clinical Practice Guideline No 11. Rockville, MD: US Department of Health and Human Services, Agency for Health Care Policy and Research; 1994: AHCPR Publication 94:6012.Google Scholar
- 26.Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995, 92:2764–2784.Google Scholar
- 27.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.Google Scholar
- 33.MICROMEDEX Healthcare Series, vol 109 [online database]. URL: http://mdx.com. Accessed June 27, 2001.Google Scholar
- 34.Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 2001.Google Scholar
- 35.Noori A, Lindenfeld J, Wolfel E, et al.: Beta-blockade in adriamycin-induced cardiomyopathy. J Cardiac Fail 2000, 6:115–119.Google Scholar